Aaron Sato, Adimab’s Chief Strategy Officer, highlights how Adimab’s pioneering antibody discovery platform drives technological breakthroughs in synthetic library evolution, multispecific generation, and developability optimization, pushing the boundaries of antibody engineering and shaping the future of therapeutics.